Syringes Market Overview Analysis By Fortune Business Insights Analysis
Market Summary
According to Fortune Business Insights: The global syringes market size was valued at USD 10.15 billion in 2025. The market is projected to grow from USD 10.64 billion in 2026 to USD 15.09 billion by 2034, exhibiting a CAGR of 4.5% during the forecast period. Asia Pacific dominated the syringes market with a market share of 35.07% in 2025.
Key Market Trends
Plastic disposable syringes continue to replace glass and reusable alternatives. Safety syringes are gaining adoption, partly beyond regulatory mandates, and interest is growing in dose-optimized and low-dead-space syringes, especially for vaccination programs. Manufacturing capacity is shifting toward Asia Pacific, particularly China and India, while developed markets emphasize differentiation, compliance, and premium safety features.
Get a Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/115104
Key Market Drivers
Injection-based therapies and immunization programs are the core driver, with an estimated 15 to 16 billion injections given globally each year. Chronic disease adds volume: over 530 million adults have diabetes (IDF, 2023), and about 129 million U.S. adults live with at least one major chronic disease (CDC, 2024). Government policies promoting safety-engineered syringes to reduce needle-stick injuries and large national immunization programs in Asia Pacific, Africa, and Latin America add further momentum.
Market Restraints
Price pressure is intense, driven by government tenders, bulk purchasing, and hospital group purchasing organizations. Billions of single-use plastic syringes create an environmental and waste burden, while strict infection control standards limit reusable syringe adoption. Regulatory compliance costs hit smaller manufacturers hardest, especially in the U.S. and Europe, and supply chains remain exposed to volatility in medical-grade plastic resin, logistics, and trade restrictions.
Market Opportunities
Healthcare infrastructure investment in Asia Pacific, the Middle East, and Africa is expanding demand. Emerging markets are moving from conventional to safety syringes as they align with WHO guidelines, although safety syringes cost more in low- and middle-income countries. Biologics, biosimilars, and injectable specialty drugs require precise dosing and smaller volumes, and homecare and self-administration, such as insulin delivery, are growing.
Segmentation Analysis
By product type, conventional syringes are the largest segment, while safety syringes are growing at an 8.6% CAGR. By volume capacity, the 1 mL to 5 mL range held a 35.3% share, and syringes up to 1 mL are growing at 6.2%. By material, plastic syringes held an 89.1% share, while glass syringes are declining at a 3.3% CAGR. By usage, disposable syringes held a 92.1% share, while reusable syringes are declining at 4.7%. By end user, hospitals and ambulatory surgical centers are dominant, with a projected 58.9% share in 2026, while pharmaceutical and biotechnology companies are growing at 7.8%, alongside clinics and clinical laboratories.
Regional Outlook
Asia Pacific led the market with USD 3.56 billion in 2025 and a projected USD 3.79 billion in 2026, with China at about USD 1.31 billion (12.3% of global), India at about USD 0.85 billion (8.0%), and Japan at about USD 0.54 billion (5.1%) in 2026.
North America is the second-largest region at USD 2.51 billion in 2026, with the U.S. at about USD 2.20 billion (20.7%).
Europe is projected at USD 2.27 billion in 2026 and growing at 3.0%, with the U.K. at USD 0.35 billion (3.4%) and Germany at 4.3% of global sales in 2025. Germany 4.3% share implies roughly USD 0.44 billion.
The GCC is projected at about USD 0.28 billion in 2026.
Connect with Our Expert for any Queries: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/115104
Competitive Landscape
The market is moderately consolidated, with a few multinationals and many regional players. Key players include Becton, Dickinson and Company, Terumo Corporation, Nipro Corporation, Gerresheimer AG, Cardinal Health, Smiths Medical, and B. Braun Melsungen AG.
In January 2025, BD announced additional U.S. manufacturing investment for IV catheters, needles, and syringes.
In May 2024, Sharps Technology signed a five-year, USD 200 million syringe sales agreement with Nephron Pharmaceuticals, tied to its acquisition of InjectEZ syringe assets in West Columbia, South Carolina.
In November 2023, Gerresheimer began a 7,500 m² plant expansion in Querétaro, Mexico, to add several hundred million ready-to-fill syringes annually for North America.
In October 2022, Terumo Pharmaceutical Solutions expanded contract development and manufacturing services for parenteral drugs, and in January 2022, ICU Medical completed its acquisition of Smiths Medical from Smiths Group.
In October 2021, BD expanded U.S. syringe and needle manufacturing under a public-private partnership with HHS's ASPR.
What Everyone Should Know About Japan’s Market Syringes Market Insights